- Home
- VMD vs ZBIO Comparison
VMD vs ZBIO Comparison
Compare VMD & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- ZBIO
- Stock Information
- Founded
- VMD 2006
- ZBIO 2019
- Country
- VMD United States
- ZBIO United States
- Employees
- VMD N/A
- ZBIO N/A
- Industry
- VMD
- ZBIO
- Sector
- VMD
- ZBIO
- Exchange
- VMD Nasdaq
- ZBIO NYSE
- Market Cap
- VMD 288.1M
- ZBIO 268.7M
- IPO Year
- VMD N/A
- ZBIO 2024
- Fundamental
- Price
- VMD $7.46
- ZBIO $7.95
- Analyst Decision
- VMD
- ZBIO Strong Buy
- Analyst Count
- VMD 0
- ZBIO 6
- Target Price
- VMD N/A
- ZBIO $31.83
- AVG Volume (30 Days)
- VMD 109.4K
- ZBIO 131.2K
- Earning Date
- VMD 03-10-2025
- ZBIO 03-25-2025
- Dividend Yield
- VMD N/A
- ZBIO N/A
- EPS Growth
- VMD 12.00
- ZBIO N/A
- EPS
- VMD 0.28
- ZBIO N/A
- Revenue
- VMD $224,257,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- VMD $23.46
- ZBIO N/A
- Revenue Next Year
- VMD $12.43
- ZBIO N/A
- P/E Ratio
- VMD $26.86
- ZBIO N/A
- Revenue Growth
- VMD 22.54
- ZBIO N/A
- 52 Week Low
- VMD $6.21
- ZBIO $5.83
- 52 Week High
- VMD $9.85
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- VMD 38.63
- ZBIO N/A
- Support Level
- VMD $7.33
- ZBIO N/A
- Resistance Level
- VMD $7.87
- ZBIO N/A
- Average True Range (ATR)
- VMD 0.25
- ZBIO 0.00
- MACD
- VMD -0.01
- ZBIO 0.00
- Stochastic Oscillator
- VMD 13.18
- ZBIO 0.00
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.